Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — Investor Presentation (April 2023)
21 slides from Alaunos Therapeutics's investor presentation, April 2023
Slide 1: Attacking Solid Tumors with Novel TCR-T Cell Therapies
Attacking Solid Tumors with Novel TCR-T Cell Therapies April 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will
Slide 3: Delivering the Promise: Revolutionizing Solid Cancer Treatment with TCR-T
Delivering the Promise: Revolutionizing Solid Cancer Treatment with TCR-T 2022 2023 2024+ Significant Accomplishments Anticipated Milestones Building for the Future First TCR-T objective clinical Phase 2 readiness Pivotal clinical trials response in solid tumors Expand TCR library to 15 Combination
Slide 4: Robust Solid Tumor Program Pipeline with Multiple Near-Term Inflection Points
Robust Solid Tumor Program Pipeline with Multiple Near- Term Inflection Points PROGRAM TARGETS INDICATION PRECLINICAL IND-ENABLING PHASE 1 PHASE 2 KRAS Lung G12D & G12V Colon/Rectum Library TCR-T Cell TP53 Endometrium R175H, R248W, Therapy Pancreas R273C & Y220C Ovary EGFR E746-A750del Bile Duct mbI
Slide 5: Driver Mutations are Ideal Targets for TCR-T Cells to Treat Solid Tumors
Driver Mutations are Ideal Targets for TCR-T Cells to Treat Solid Tumors Target Examples Key Advantages Key Disadvantages • Drives cancer • Highly expressed targets Driver Mutations Mutated EGFR, KRAS or TP53 • Single targets • Not on normal tissue • Large addressable market • Small addressable mark
Slide 6: Alaunos Evaluating TCR-T Against the Most Frequently Mutated Genes in Solid Tumors
Alaunos Evaluating TCR-T Against the Most Frequently Mutated Genes in Solid Tumors: KRAS, TP53, EGFR Nearly 2 million solid tumors cases diagnosed in United States annually Limited approved drugs for these high value targets These six indications represent ~600,000 new cases per year 6 Source: Most
Slide 7: Confirmed Responses from Leading Academic Institutions Corroborate Targeting Driver Mutations
Confirmed Responses from Leading Academic Institutions Corroborate Targeting Driver Mutations with TCR-T Cells Greater than 70% tumor reduction of metastatic 55% tumor reduction of metastatic breast cancer six pancreatic cancer six months after infusion of KRAS-G12D months after infusion of TP53-R17
Slide 8: Differentiated Approach to Convert Natural T-Cell Responses into TCR-T Cell Therapy
Differentiated Approach to Convert Natural T-Cell Responses into TCR-T Cell Therapy for a Broad Patient Population TCR Source TCR Library Manufacture TCR-T Cell Therapy Natural TIL 1. Isolate Reactive Autologous TCR-T Response to TCR to Target A Cells Reactive to Target A Target A 2. Make Sleeping B
Slide 9: Industry Leading TCR Library Captures Both High Frequency Mutations and HLA Types
Industry Leading TCR Library Captures Both High Frequency Mutations and HLA Types Two-pronged library expansion strategy: 1. Add more HLAs to existing mutations 2. Add more mutations to KRAS, TP53, EGFR Our TCR library contains mutations from genes that are known to drive cancer and are highly expre
Slide 10: Non-viral Sleeping Beauty Platform Ideal for Manufacturing TCR-T Cells
Non-viral Sleeping Beauty Platform Ideal for Manufacturing TCR-T Cells without Complexity of Gene Editing • Efficient, essentially random integration without complexity of gene editing or viral approaches • Rapid, cost-effective manufacturing • Flexible approach to add TCRs; attractive choice for li
Slide 11: TCR-T Cells Recognize KRAS, TP53, EGFR Mutations and Kill Solid Tumor Cells
TCR-T Cells Recognize KRAS, TP53, EGFR Mutations and Kill Solid Tumor Cells Powerful TCRs: Naturally-occurring, high avidity TCRs recognize low levels of neoantigens No off-target toxicity observed: Specificity for the mutation with negligible recognition of wild type sequences Tumor killing: Recogn
Slide 12: TCR-T Cell Products are Manufactured with a TCR Matched to Each Patient's Tumor Mutation
TCR-T Cell Products are Manufactured with a TCR Matched to Each Patient’s Tumor Mutation and HLA Type Screening 1 2 Infusion 7 Selection of TCR from Library for Manufacturing Formulation & 3 Cryopreservation 6 Peripheral Blood Leukapheresis 5 4 Sleeping Beauty Transposition of TCR TCR Expression & E
Slide 13: Universal, In-House Manufacturing Platform Delivers High Quality TCR-T Cell Products
Universal, In-House Manufacturing Platform Delivers High Quality TCR-T Cell Products Ongoing Process Optimization Patient 1 Patient 2 Patient 3 Mutation KRAS-G12D TP53-R175H KRAS-G12V Automation and closed process steps to increase throughput Indication Lung Colorectal Pancreatic Dose Level One Two
Slide 14: First-in-Human TCR-T Clinical Trial Actively Enrolling with Innovative Library Approach
First-in-Human TCR-T Clinical Trial Actively Enrolling with Innovative Library Approach • Defines safety and dose with any TCR and any indication Phase 1 • Enrolling in one of three dose cohorts: 5, 40 and 100 billion TCR-T cells • Defines efficacy at recommended dose with any TCR in library Phase 2
Slide 15: First-in-Human Confirmed Response in Solid Tumors by Sleeping Beauty TCR-T Cell Therapy
First-in-Human Confirmed Response in Solid Tumors by Sleeping Beauty TCR-T Cell Therapy SAFETY PERSISTENCE EFFICACY Manageable safety profiles Persisting TCR-T cells First TCR-T cell response in in first two dose levels (20%-30%) in blood checkpoint inhibitor refractory NSCLC No DLTs TCR-T cells tra
Slide 16: Patient 1 Showed Durable, Complete Resolution of NSCLC Lesion Through Six Months
Patient 1 Showed Durable, Complete Resolution of NSCLC Lesion Through Six Months Insert Image Here Insert Image Here 0 6 12 24 Baseline Week 6 Week 12 Week 24 • Patient 1 had multiple lines of prior therapy and was refractory to checkpoint inhibitors • Treated with 9 billion TCR-T cells (dose level
Slide 17: TCR-T Cells Persist in Blood and Traffic to Tumor Microenvironment
TCR-T Cells Persist in Blood and Traffic to Tumor Microenvironment Mutation and HLA were present in Patient 1: post-treatment tumors TCR-T Cell Persistence in Blood Six-month Tumor Biopsy 100 Patient 1 TCR-T Cells in Blood (%) Patient 2 80 TCR-T 6.1% TCR-T cells were detected in TCR-T 60 peripheral
Slide 18: Next-Generation TCR-T Efforts Aim to Deepen Clinical Responses
Next-Generation TCR-T Efforts Aim to Deepen Clinical Responses Augmenting TCR-T Survival Combine TCR-T and Immune Multiple TCRs Infused into via Co-Expression of mbIL-15 Checkpoint Inhibitors the Same Patient Regeneration of effector Reinvigorate TCR-T cells in the Attack multiple targets on the tum
Slide 19: hunTR Expands TCR Library, Increases Addressable Market and Enables Multiplexed TCR-T
hunTR® Expands TCR Library, Increases Addressable Market and Enables Multiplexed TCR-T Cell Therapy 2024+ Add new HLAs to existing mutations and add 40+ more key mutations within EGFR, KRAS, TP53 TCRs 2023 Matching data from clinical efforts inform which 15 Potential Patients per Year HLA/mutation c
Slide 20: Experienced Management Team
Experienced Management Team Kevin S. Boyle, Sr. Melinda Lackey Chief Executive Officer SVP Legal Drew Deniger, PhD Abhishek Srivastava, PhD Mike Wong VP Research & Development VP Technical Operations VP Finance Melinda Lackey 20
Slide 21: 2023 Milestones Designed to Cement Our Leadership Position in TCR-T Cell Therapy
2023 Milestones Designed to Cement Our Leadership Position in TCR-T Cell Therapy for the Treatment of Solid Tumors Advance TCR-T Optimize New IND for Expand TCR Library to 15 Library trial to manufacturing mbIL-15 TCR-T TCRs Phase 2 process towards commercial Translational assessment- scalability dr
Alaunos Therapeutics — Investor Presentation (April 2023) on 6ix